Pharmacovigilance : (Record no. 1961)
000 -LEADER | |
---|---|
fixed length control field | 04569cam a2200505 i 4500 |
001 - CONTROL NUMBER | |
control field | 22132886 |
003 - CONTROL NUMBER IDENTIFIER | |
control field | OSt |
005 - DATE AND TIME OF LATEST TRANSACTION | |
control field | 20250823191646.0 |
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
fixed length control field | 210714s2019 mouab b 001 0 eng c |
010 ## - LIBRARY OF CONGRESS CONTROL NUMBER | |
LC control number | 2021301538 |
016 7# - NATIONAL BIBLIOGRAPHIC AGENCY CONTROL NUMBER | |
Record control number | 101738270 |
Source | DNLM |
020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
International Standard Book Number | 9780323581165 |
Qualifying information | pbk. |
020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
International Standard Book Number | 0323581161 |
Qualifying information | pbk. |
035 ## - SYSTEM CONTROL NUMBER | |
System control number | (OCoLC)on1015855399 |
040 ## - CATALOGING SOURCE | |
Original cataloging agency | NLM |
Language of cataloging | eng |
Transcribing agency | NLM |
Description conventions | rda |
Modifying agency | YDX |
-- | OCLCF |
-- | OCLCO |
-- | OCLCA |
-- | DLC |
042 ## - AUTHENTICATION CODE | |
Authentication code | pcc |
050 00 - LIBRARY OF CONGRESS CALL NUMBER | |
Classification number | RM302.5 |
Item number | .D63 2019 |
060 00 - NATIONAL LIBRARY OF MEDICINE CALL NUMBER | |
Classification number | 2018 I-615 |
060 10 - NATIONAL LIBRARY OF MEDICINE CALL NUMBER | |
Classification number | QV 771 |
100 1# - MAIN ENTRY--PERSONAL NAME | |
Personal name | Doan, Thao, |
Relator term | author. |
245 10 - TITLE STATEMENT | |
Title | Pharmacovigilance : |
Remainder of title | a practical approach / |
Statement of responsibility, etc. | Thao Doan, Cheryl Renz, Mondira Bhattacharya, Fabio Lievano, Linda Scarazzini. |
264 #1 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
Place of production, publication, distribution, manufacture | St. Louis, Missouri : |
Name of producer, publisher, distributor, manufacturer | Elsevier, |
Date of production, publication, distribution, manufacture, or copyright notice | [2019] |
300 ## - PHYSICAL DESCRIPTION | |
Extent | xiv, 213 pages : |
Other physical details | color illustrations, color maps ; |
Dimensions | 24 cm |
336 ## - CONTENT TYPE | |
Content type term | text |
Content type code | txt |
Source | rdacontent |
337 ## - MEDIA TYPE | |
Media type term | unmediated |
Media type code | n |
Source | rdamedia |
338 ## - CARRIER TYPE | |
Carrier type term | volume |
Carrier type code | nc |
Source | rdacarrier |
504 ## - BIBLIOGRAPHY, ETC. NOTE | |
Bibliography, etc. note | Includes bibliographical references and index. |
505 0# - FORMATTED CONTENTS NOTE | |
Formatted contents note | Front Cover; Pharmacovigilance: A Practical Approach; Pharmacovigilance: A Practical Approach; Copyright; List of Contributors; Acknowledgments; Introduction; Contents; I -- THE REGULATORY ENVIRONMENT; 1 -- Does Regulation Drive Science or Does Science Drive Regulation?; INTRODUCTION; IMPORTANT EVENTS IN PHARMACOVIGILANCE; IMPORTANT PHARMACOVIGILANCE ORGANIZATIONS; IMPORTANT REGULATORY AUTHORITIES AND REGIONS; THE WORLD OF REGULATORY SCIENCE; EMA PHARMACOVIGILANCE RISK ASSESSMENT COMMITTEE; NEW WAVE OF GLOBAL PHARMACOVIGILANCE REGULATION; THE EU QPPV; THE RISE OF THE NATIONAL QPPV |
505 8# - FORMATTED CONTENTS NOTE | |
Formatted contents note | The Pharmacovigilance System Master FileIs Regulatory Guidance Just Guidance?; How can Industry Influence Regulation?; Enforcement of Pharmacovigilance Regulations; CONCLUSIONS; REFERENCES; II -- SAFETY DATA AND REAL WORLD EVIDENCE; 2 -- Signal Management and Methods of Signal Detection; INTRODUCTION; SIGNALS (BOX 2.2); SIGNAL DETECTION; SIGNAL VALIDATION; SIGNAL ASSESSMENT; DETERMINING BENEFIT/RISK (BOX 2.5); SAFETY GOVERNANCE IN PHARMACOVIGILANCE; SAFETY GOVERNANCE FRAMEWORK; SAFETY OVERSIGHT BOARD (BOX 2.8); SAFETY MANAGEMENT TEAMS 18; FIRST-IN-HUMAN REVIEW COMMITTEE 19,20 |
505 8# - FORMATTED CONTENTS NOTE | |
Formatted contents note | INTERNAL SAFETY ADVISORY GROUPS SAFETY ASSESSMENT COMMITTEES 21; SAFETY GOVERNANCE SUPPORT; SAFETY GOVERNANCE PROCESS (BOX 2.11); CONCLUSION; LIST OF DEFINITIONS; REFERENCES; FURTHER READING; 3 -- Product Safety Monitoring in Clinical Trials; INTRODUCTION; SAFETY PLANNING; Systemic Approach; Development Risk Management Plan and Development Core Safety Information (Box 3.3); Specific Safety Issues (Box 3.4); DATA COLLECTION AND EVALUATION; Data Collection (Box 3.5); General principles and considerations; Specialized data collection and adjudication; Baseline risk factor documentation |
505 8# - FORMATTED CONTENTS NOTE | |
Formatted contents note | Safety topics of interest Event adjudication; Data monitoring committee (Box 3.6); Safety assessment committees; Data Evaluation; Quantitative analysis; Individual studies (Box 3.8); Individual studies (Box 3.8); Meta-Analysis (Box 3.11); Meta-Analysis (Box 3.11); Qualitative analysis (Box 3.12); Signal evaluation; Safety actions in response to a confirmed signal-risk management (Box 3.13); REPORTING AND COMMUNICATION OF SAFETY INFORMATION; Expedited Reporting; Causality assessment of individual case safety report (Box 3.14); Communicating Safety Information (Box 3.16); Informed consent |
505 8# - FORMATTED CONTENTS NOTE | |
Formatted contents note | Investigator brochure Development Safety Update Report; CONCLUSION; REFERENCES; 4 -- Causality Assessment and Examples of Adverse Drug Reactions (Drug-Induced Liver Injury, Renal, Skin, and Major ...; INTRODUCTION; THE CIOMS WORKING GROUP CRITERIA; THE BRADFORD-HILL CRITERIA; LIVER: CAUSALITY ASSESSMENT IN DRUG-INDUCED LIVER INJURY IN ADULTS; Step 1: Take History and Perform a Physical Examination; Step 2: Calculate the R-Value; Step 3: Exclude Differential Diagnoses; Step 4: Literature Review; Step 5: Clinical Judgement for Final Drug-Induced Liver Injury Diagnosis |
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Pharmacovigilance. |
650 12 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Pharmacovigilance. |
650 22 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Drug Monitoring. |
650 22 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Patient Safety. |
650 #7 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name entry element | Pharmacovigilance. |
Source of heading or term | fast |
Authority record control number or standard number | (OCoLC)fst02002642 |
700 1# - ADDED ENTRY--PERSONAL NAME | |
Personal name | Renz, Cheryl, |
Relator term | author. |
700 1# - ADDED ENTRY--PERSONAL NAME | |
Personal name | Bhattacharya, Mondira, |
Titles and other words associated with a name | MD, |
Relator term | author. |
700 1# - ADDED ENTRY--PERSONAL NAME | |
Personal name | Lievano, Fabio, |
Relator term | author. |
700 1# - ADDED ENTRY--PERSONAL NAME | |
Personal name | Scarazzini, Linda, |
Relator term | author. |
906 ## - LOCAL DATA ELEMENT F, LDF (RLIN) | |
a | 7 |
b | cbc |
c | pccadap |
d | 2 |
e | ncip |
f | 20 |
g | y-gencatlg |
942 ## - ADDED ENTRY ELEMENTS (KOHA) | |
Source of classification or shelving scheme | Library of Congress Classification |
Koha item type | Books |
Suppress in OPAC | No |
Withdrawn status | Lost status | Source of classification or shelving scheme | Damaged status | Not for loan | Home library | Current library | Shelving location | Date acquired | Total checkouts | Full call number | Barcode | Date last seen | Price effective from | Koha item type |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Library of Congress Classification | 2nd Floor Main Library | 2nd Floor Main Library | General stacks | 06/17/2025 | RM302.5 .D63 2019 | 101863 | 06/17/2025 | 06/17/2025 | Books |